Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the companys early feasibility study (EFS) to evaluate DurAVR THV. This unique device represents a new class of biomimetic valve and stands as the world's only balloon-expandable, single-piece transcatheter aortic valve. The study aims to assess the safety and feasibility of DurAVR THV in treating 15 patients suffering from symptomatic, severe native aortic stenosis, and is critical to obtaining US Food and Drug Administration clearance.
Anteris is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.
The Companys lead product, DurAVRTM, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVRTM THV was designed in partnership with the worlds leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.
DurAVRTM THV is made using ADAPT tissue, Anteris patented anti-calcification tissue technology. ADAPT tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/anteris-talks-market-superiority-of-its-biomimetic-tavr-valve-713311150
Anteris Technologies Ltd
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Gio News UK journalist was involved in the writing and production of this article.